BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1009 related articles for article (PubMed ID: 23470568)

  • 21. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.
    Yachida S; White CM; Naito Y; Zhong Y; Brosnan JA; Macgregor-Das AM; Morgan RA; Saunders T; Laheru DA; Herman JM; Hruban RH; Klein AP; Jones S; Velculescu V; Wolfgang CL; Iacobuzio-Donahue CA
    Clin Cancer Res; 2012 Nov; 18(22):6339-47. PubMed ID: 22991414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P53 immunolabeling in EUS-FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with neoadjuvant therapy.
    Oshima M; Okano K; Kamada H; Suto H; Ando Y; Ibuki E; Ishikawa R; Masaki T; Haba R; Suzuki Y
    J Hepatobiliary Pancreat Sci; 2023 Jun; 30(6):802-814. PubMed ID: 36448271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.
    Schlitter AM; Segler A; Steiger K; Michalski CW; Jäger C; Konukiewitz B; Pfarr N; Endris V; Bettstetter M; Kong B; Regel I; Kleeff J; Klöppel G; Esposito I
    Sci Rep; 2017 Feb; 7():41064. PubMed ID: 28145465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.
    Masugi Y; Takamatsu M; Tanaka M; Hara K; Inoue Y; Hamada T; Suzuki T; Arita J; Hirose Y; Kawaguchi Y; Nakai Y; Oba A; Sasahira N; Shimane G; Takeda T; Tateishi K; Uemura S; Fujishiro M; Hasegawa K; Kitago M; Takahashi Y; Ushiku T; Takeuchi K; Sakamoto M;
    J Pathol Clin Res; 2023 Sep; 9(5):339-353. PubMed ID: 37291757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
    Yamada S; Fujii T; Shimoyama Y; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
    Pancreas; 2015 May; 44(4):660-4. PubMed ID: 25760429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.
    Izeradjene K; Combs C; Best M; Gopinathan A; Wagner A; Grady WM; Deng CX; Hruban RH; Adsay NV; Tuveson DA; Hingorani SR
    Cancer Cell; 2007 Mar; 11(3):229-43. PubMed ID: 17349581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).
    de vos tot Nederveen Cappel WH; Offerhaus GJ; van Puijenbroek M; Caspers E; Gruis NA; De Snoo FA; Lamers CB; Griffioen G; Bergman W; Vasen HF; Morreau H
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3598-605. PubMed ID: 14506146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
    Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
    Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
    Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
    Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.
    Tascilar M; Skinner HG; Rosty C; Sohn T; Wilentz RE; Offerhaus GJ; Adsay V; Abrams RA; Cameron JL; Kern SE; Yeo CJ; Hruban RH; Goggins M
    Clin Cancer Res; 2001 Dec; 7(12):4115-21. PubMed ID: 11751510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.
    Lenz J; Karasek P; Jarkovsky J; Muckova K; Dite P; Kala Z; Veselska R; Hermanova M
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):389-96. PubMed ID: 22187705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
    Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
    [No Abstract]   [Full Text] [Related]  

  • 34. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9.
    Ono M; Ono Y; Nakamura T; Tsuchikawa T; Kuraya T; Kuwabara S; Nakanishi Y; Asano T; Matsui A; Tanaka K; Ebihara Y; Kurashima Y; Noji T; Murakami S; Shichinohe T; Mitsuhashi T; Omori Y; Furukawa T; Taniue K; Suzuki M; Sugitani A; Karasaki H; Mizukami Y; Hirano S
    Ann Surg Oncol; 2022 Aug; 29(8):5007-5019. PubMed ID: 35399143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4.
    Hosoda W; Chianchiano P; Griffin JF; Pittman ME; Brosens LA; Noë M; Yu J; Shindo K; Suenaga M; Rezaee N; Yonescu R; Ning Y; Albores-Saavedra J; Yoshizawa N; Harada K; Yoshizawa A; Hanada K; Yonehara S; Shimizu M; Uehara T; Samra JS; Gill AJ; Wolfgang CL; Goggins MG; Hruban RH; Wood LD
    J Pathol; 2017 May; 242(1):16-23. PubMed ID: 28188630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts.
    Argani P; Shaukat A; Kaushal M; Wilentz RE; Su GH; Sohn TA; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Cancer; 2001 Apr; 91(7):1332-41. PubMed ID: 11283934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions.
    Parwani AV; Geradts J; Caspers E; Offerhaus GJ; Yeo CJ; Cameron JL; Klimstra DS; Maitra A; Hruban RH; Argani P
    Mod Pathol; 2003 Apr; 16(4):299-308. PubMed ID: 12692194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
    Peng B; Fleming JB; Breslin T; Grau AM; Fojioka S; Abbruzzese JL; Evans DB; Ayers D; Wathen K; Wu T; Robertson KD; Chiao PJ
    Clin Cancer Res; 2002 Nov; 8(11):3628-38. PubMed ID: 12429655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous deregulation of p16 and cyclin D1 genes in pancreatic ductal adenocarcinoma: a combined immunohistochemistry and image analysis study based on tissue microarrays.
    Tsiambas E; Karameris A; Gourgiotis S; Salemis N; Athanassiou AE; Karakitsos P; Papalois A; Merikas E; Kosmidis P; Patsouris E
    J BUON; 2007; 12(2):261-7. PubMed ID: 17600882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics.
    Choi SH; Kim HJ; Kim KW; An S; Hong SM; Kim SC; Kim MH
    Br J Radiol; 2017 May; 90(1073):20160403. PubMed ID: 28339284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.